Bleomycin A6
Also known as: Bleomycin A6, Bleomycin A6 (Pinyangmycin), Bleomycin sulfate, BLM A6, BLM-A6, Boanmycin, Pingyangmycin
Source Bleomycin A6 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Bleomycin A6 is a glycopeptide antibiotic that functions as an antineoplastic drug. It is approved for prescription use and is administered by parenteral routes (intravenous, intramuscular, subcutaneous, intralesional). Pre‑clinical work has shown activity against several solid tumours, and early‑phase clinical testing has explored its safety in humans.
Mechanism of Action
The antitumour activity of Bleomycin A6 is linked to its terminal polyamine moiety, which can generate hydrogen peroxide and acrolein in the presence of amine oxidase. These reactive species cause oxidative damage to cellular macromolecules, including DNA, leading to cell death. The same oxidative pathway underlies the drug’s known pulmonary fibrogenic potential when the compound reaches lung tissue.
What the Research Shows
Animal studies demonstrated strong cytotoxicity of Bleomycin A6 against human colon (HT‑29, Hce‑8693) and liver (BEL‑7402) cancer cells, producing up to 90% tumour growth inhibition in xenograft models and outperforming 5‑fluorouracil and mitomycin C in colon cancer. Conjugation to a hepatoma‑specific monoclonal antibody increased tumour targeting and achieved 78% inhibition of liver tumour growth, with minimal off‑target toxicity. A liposome‑in‑gel delivery system prolonged local drug residence for at least five days in vivo, suggesting potential for sustained release. A Phase I trial in 36 patients reported no myelosuppression or cardiac toxicity, with fever, gastrointestinal upset and injection‑site hardening as the most common adverse events; the maximum tolerated dose was not reached.
Reported Benefits
Pre‑clinical data indicate that Bleomycin A6 can produce potent tumour regression, particularly in colon and liver cancer models, and may be more effective than some standard chemotherapeutics. Antibody‑drug conjugates appear to enhance tumour selectivity, while liposomal gel formulations could extend drug exposure at the injection site, potentially reducing dosing frequency.
Limitations of the Evidence
Evidence of efficacy is confined to animal models and a small, non‑randomised Phase I human study; no controlled clinical trials have confirmed therapeutic benefit. Pulmonary fibrosis observed after intratracheal exposure in rats raises safety concerns for lung exposure. Renal toxicity emerges at doses above 2 mg kg⁻¹ in rodents, and the optimal therapeutic dose in humans remains undefined.
Safety Considerations
Toxicology studies show dose‑dependent renal injury in rats and lung fibrosis in rats after intratracheal administration, linked to the polyamine‑derived reactive oxygen species. In dogs, higher intravenous doses caused renal damage and skin ulceration. The Phase I trial reported fever (individual‑related), gastrointestinal symptoms, injection‑site hardening, mild myalgia, alopecia, rash and skin pigmentation, all of which resolved after stopping treatment. Patients with pre‑existing renal or pulmonary disease may experience worsening of organ function.
How It Is Administered
Bleomycin A6 is supplied for parenteral use and can be given intravenously, intramuscularly, subcutaneously or intralesionally. Experimental formulations include anionic liposome‑loaded in situ gels designed for sustained release after injection. No oral formulation is currently approved.
Routes of Administration
Goals & Uses
- Hodgkin lymphoma treatmentOncologyHigh
- Lymphoma treatmentOncologyModerate
- Testicular carcinoma treatmentOncologyModerate
- Hemangioma treatmentDermatology/PediatricsLow
- Squamous cell carcinoma treatmentOncologyModerate
- Vascular malformation sclerotherapyInterventional RadiologyModerate
- Testicular cancer adjuvant therapyOncologyHigh
Contraindications
- Severely impaired renal functionRenalHigh
- Hypersensitivity to bleomycin compoundsImmunologicHigh
- Known hypersensitivity to bleomycinImmuneHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Pulmonary fibrosis or severe lung diseasePulmonaryHigh
- Pulmonary fibrosisRespiratoryHigh
Adverse Effects
- Oral mucositis / stomatitisMucosalUncommon
- Fever and chillsConstitutionalCommon
- Nausea and vomitingGastrointestinalUncommon
- Anaphylactoid reactionImmunologicRare
- MucositisGastrointestinal / MucosalUncommon
- Skin hyperpigmentationDermatologicCommon
- Pulmonary toxicity / pulmonary fibrosisPulmonaryUncommon
- Pulmonary toxicityRespiratoryCommon
- Mucocutaneous toxicity (skin thickening, hyperpigmentation, alopecia)DermatologicCommon
Drug Interactions
- Supplemental oxygen (high FiO2)High
- G-CSF / GM-CSFModerate
- CisplatinHigh
- Vinca alkaloids (vincristine, vinblastine)Low
- High inspired oxygen concentrationsHigh
- Other DNA‑damaging agents (e.g., cisplatin)Moderate
Population Constraints
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveAbsolute
- Patients with renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- Elderly patients (≥65 years)Age RelatedRelative
Regulatory Status
- European UnionApprovedApproved: Hodgkin lymphoma, Testicular cancerEMA approval with similar restrictions on pulmonary toxicity.
- United StatesApprovedApproved: Hodgkin lymphoma, Testicular cancer, Squamous cell carcinoma of head and neckFDA‑approved as bleomycin sulfate for IV/IM administration.
- United KingdomUnapprovedMHRA approvals cover bleomycin sulfate (A2/B2); Bleomycin A6 not separately licensed.
Approved for Hodgkin lymphoma, testicular cancer, squamous cell carcinoma of the head and neck; dosing limited by pulmonary toxicity risk.
Evidence & Sources
- Journal ArticleLowDing W, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleLowPeng Z, Zhen YS1991-01-01T00:00:00.000000Z
- Journal ArticleLowDeng Y1990-01-01T00:00:00.000000Z
- Journal ArticleLowLin FT1989-01-01T00:00:00.000000Z
- Journal ArticleLowNewman RA, Hacker MP, Sakai TT1983-01-01T00:00:00.000000Z
- Journal ArticleModerateFeng F, et al.1996-01-01T00:00:00.000000Z
Frequently Asked Questions
What types of cancer have been studied with Bleomycin A6?
Pre‑clinical work has focused on colon, cecum and liver cancer xenografts, where the drug produced marked tumour inhibition. No large‑scale human trials have yet confirmed efficacy in these or other cancers.
Is Bleomycin A6 associated with lung toxicity?
Yes. In rats, intratracheal administration caused pulmonary fibrosis, and the drug’s polyamine component can generate hydrogen peroxide and acrolein, which are implicated in lung injury. Caution is advised in patients with existing lung disease.
How is Bleomycin A6 given in clinical practice?
It is administered by injection—intravenous, intramuscular, subcutaneous or intralesional. Experimental delivery systems such as liposome‑in‑gel have been explored to prolong local drug presence, but standard practice uses aqueous solutions.
What are the common side effects observed in humans?
In a Phase I study, the most frequent adverse events were fever (individual‑related), gastrointestinal upset, hardening at the injection site, mild myalgia, alopecia, skin rash and pigmentation. No myelosuppression or cardiac toxicity was reported.
Can Bleomycin A6 be combined with other chemotherapies?
The cited studies do not provide data on combination regimens. Its use alongside other agents would need to be evaluated in controlled clinical trials to assess safety and potential synergistic effects.
What is Bleomycin A6?
Bleomycin A6 is a glycopeptide antibiotic that functions as an antineoplastic drug. It is approved for prescription use and is administered by parenteral routes (intravenous, intramuscular, subcutaneous, intralesional). Pre‑clinical work has shown activity against several solid tumours, and early‑phase clinical testing has explored its safety in humans.
What is Bleomycin A6 used for?
Bleomycin A6 is educationally associated with: Hodgkin lymphoma treatment, Lymphoma treatment, Testicular carcinoma treatment, Hemangioma treatment, Squamous cell carcinoma treatment, Vascular malformation sclerotherapy, Testicular cancer adjuvant therapy. Educational only — not medical advice.
How is Bleomycin A6 administered?
Recorded routes of administration: Intralesional, Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Bleomycin A6?
Reported adverse effects include: Oral mucositis / stomatitis, Fever and chills, Nausea and vomiting, Anaphylactoid reaction, Mucositis, Skin hyperpigmentation, Pulmonary toxicity / pulmonary fibrosis, Pulmonary toxicity, Mucocutaneous toxicity (skin thickening, hyperpigmentation, alopecia). This list is not exhaustive — consult a qualified clinician.
Who should avoid Bleomycin A6?
Recorded contraindications: Severely impaired renal function, Hypersensitivity to bleomycin compounds, Known hypersensitivity to bleomycin, Pregnancy, Pulmonary fibrosis or severe lung disease, Pulmonary fibrosis. Consult a qualified clinician before use.